Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PacificGMP Manufactures Fusion Protein for Vasgene | Contract Pharma

What are you searching for?

Sign in
Breaking News

PacificGMP Manufactures Fusion Protein for Vasgene

Cancer therapeutic will be used for Phase I trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PacificGMP and Vasgene Therapeutics have successfully completed the large-scale cGMP manufacture of Vasgene’s recombinant fusion protein for use in a Phase I trial. “Using our 500-liter capacity Wave bioreactor platform, we produced and subsequently purified enough of Vasgene’s recombinant fusion protein to aseptically fill more than 2,500 vials,” said Kristin DeFife, vice president of operations at PacificGMP. “We worked very closely with the scientists at Vasgene and welcomed their person-in-plant to ensure the success of this important project.”
 
“We selected PacificGMP as our CMO because of their considerable expertise in scale-up and cGMP manufacturing of proteins using single use technology as well as for their commitment to being a partner in our efforts to bring this product to the clinic. We are very pleased with PacificGMP’s manufacture of Vasgene’s recombinant fusion protein to support development of this cancer therapeutic agent,” said Parkash Gill, M.D., Vasgene’s co-founder and director.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics